At week @ , canagliflozin @ and @mg were associated with reductions in HbA@c versus placebo ( -@ and -@ % vs @ % , respectively ; overall mean baseline , @ % ) and more patients achieved HbA@c < @ % with canagliflozin @ and @mg than with placebo ( @ and @ % vs @ % , respectively ) .